Cortice Biosciences Announces Enrollment Of A Clinical Trial Targeting Tau Dysfunction In Mild-To-Moderate Alzheimer's Disease
Published: Jan 21, 2014
NEW YORK, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that enrollment has begun in a Phase 1 open-label dose-escalation trial designed to evaluate safety, tolerability and preliminary efficacy of the company's lead drug candidate, TPI 287, for treatment of patients with mild-to-moderate Alzheimer's disease (www.clinicaltrials.gov ID NCT01966666). TPI 287 is an abeotaxane, a taxoid that binds to and stabilizes microtubules (MTs) similarly to the taxanes, paclitaxel and docetaxel. A distinct advantage of TPI 287 over the taxanes is an ability to readily cross the blood-brain barrier.
Help employers find you! Check out all the jobs and post your resume.